Skadden, Arps, Slate, Meagher & Flom and Zhong Lun Law Firm have advised China’s Everest Medicines on its $451 million IPO in Hong Kong, with Kirkland & Ellis and Tian Yuan Law Firm advising the joint sponsors and underwriters.

Everest Medicines, a China-based clinical-stage biopharmaceutical company created by C-Bridge Capital in July 2017, develops, licenses and commercialises potentially novel transformative therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets.

It is the second Chinese biopharmaceutical company to go public in Hong Kong this month, after JHBP (CY) Holdings.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Features

BRIEF: Malaysia Offers Investors Cooling IPO Respite During Sluggish Summer

by Sarah Wong |

In a year when global IPO markets have wilted under the economic heat, Bursa Malaysia has stood out as a surprising oasis of activity.

Deals

JSA, Trilegal act on NTPC Green’s upcoming $1.2bln IPO

by Nimitt Dixit |

JSA Advocates & Solicitors is advising NTPC Green Energy, state-run power producer National Thermal Power Corporation’s renewable energy arm, on its announced initial public offering worth $1.2 billion, with Trilegal advising the book running lead managers.

Deals

CAM, Khaitan, Links act on Bajaj Housing Finance’s $782mln IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Indian home-loan financier Bajaj Housing Finance (BHF) and its promoter Bajaj Finance on BHF’s $782 million initial public offering, with Khaitan & Co and Linklaters representing the book-running lead managers to the offer.